Cooler but still well above normal this week

MPR News helps you turn down the noise and build shared understanding. Turn up your support for this public resource and keep trusted journalism accessible to all. 

Turn Up Your Support

A large study of the drug hydroxychloroquine has been 

The paper, published in the journal the Lancet last month, concluded that hydroxychloroquine, taken either alone or with an antibiotic, to treat patients with COVID-19 was of no benefit and actually increased a patient's risk of dying.

The publication of the study prompted the World Health Organization (WHO) to

 of hydroxychloroquine. The WHO has now resumed the trial.

The Lancet paper analyzed data, purported to be from COVID-19 patients in more than 600 hospitals around the world. The data were collected by a private company called 

Concerns were raised about the accuracy of the data and the paper started attracting criticism within days of its publication.  In an

Lancet more than a hundred scientists and clinicians asked the journal to provide details about the data and called for the study to be independently validated.

So the Lancet launched an independent review and asked Surgisphere to transfer their complete database for evaluation.  Surgisphere agreed to the review, but the third party reviewers told the

Lancet that they were not able to access all the data, because the company said this would violate client agreements and confidentiality requirements.

It was this failure to independently audit the data that prompted three of the study's authors to retract the paper, saying they "can no longer vouch for the veracity of the primary data sources."

The Lancet issued a statement saying it takes issues of scientific integrity "extremely seriously," and there are still many outstanding questions about Surgisphere and the data used in the study.

 pledging transparency, and says it is working to address all questions about the data it provided.  

Health

COVID-19

Jane Greenhalgh

Author

A paper suggesting hydroxychloroquine increases the risk of death for patients with COVID-19 has been retracted by three of its authors because they were not able to verify the data used in the study.

Authors retract hydroxychloroquine study, citing concern over data

Go Deeper.

Like this?

News you can use in your inbox